Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsBusiness Wire • 02/27/25
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical OfficerBusiness Wire • 01/24/25
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 MillionBusiness Wire • 12/07/24
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 12/05/24
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: AnalystBenzinga • 12/03/24
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer PatientsInvestors Business Daily • 12/03/24
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPCBusiness Wire • 12/02/24
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion StudiesBusiness Wire • 11/25/24
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsBusiness Wire • 11/06/24
Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?Zacks Investment Research • 09/13/24
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/24
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsBusiness Wire • 08/07/24
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsBusiness Wire • 05/07/24